|
KMID : 0370220180620030158
|
|
Yakhak Hoeji
2018 Volume.62 No. 3 p.158 ~ p.170
|
|
|
Market Trends of antibody-drug conjugate and its new platform technologies
|
|
Shin Seok-Ho
Park Min-Ho
Byeon Jin-Ju
Lee Byeong-Ill
Park Yu-Ri
Choi Jang-Mi
Kim Na-Hye
Shin Young-Geun
|
|
|
Abstract
|
|
|
|
The antibody-drug conjugate (ADC) is one of the most rapidly growing next generation antibody therapies used in oncology, autoimmunity and chronic inflammatory diseases. ADC is consisted of monoclonal antibody conjugated via chemical linker with highly cytotoxic small molecules, called payloads. Due to the rising prevalence of cancer and population aging, there is a consistent unmet needs on novel therapeutics for patients where the traditional antibody therapy does not work. With the successful market settlement of FDA-approved Adcetris® and Kadcyla®, global pharmaceutical companies have put their resources for development of this innovative drug class. There are still some drawbacks in this class of drug including linker stability and heterogenous drug antibody ratio (DAR) profile. However new platform technologies are making progress to overcome these problems and further investment will drive growth in the next generation antibody therapies market. In this manuscript, we review the market drivers and restraints and introduce four approved ADCs. We then mainly discuss the important aspects considered while developing ADCs (cytotoxic drug, linker, DAR) and ADC platforms widely used in the industries.
|
|
|
KEYWORD
|
|
|
Antibody-drug conjugate, linker chemistry, next generation biotherapeutics, ADC platform
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|